Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Net income was −$70M. Operating cash flow of −$72M less capital expenditure of $24,000 left free cash flow of −$72M.
Last 5 fiscal years
| Fiscal year | Dec 2024 | Dec 2025 |
|---|---|---|
| Research & development | 23.3 | 62.1 |
| Operating income | −26.8 | −72.3 |
| Interest expense | 0.6 | 0.0 |
| Pre-tax income | −26.5 | −70.0 |
| Income tax | 0.0 | 0.0 |
| Net income | −26.5 | −70.0 |
| Diluted EPS | −37.05 | −111.91 |
| Diluted shares | 0.7 | 0.7 |
| Fiscal year | Dec 2024 | Dec 2025 |
|---|---|---|
| Cash & equivalents | 53.1 | 21.8 |
| Current assets | 55.5 | 152 |
| Net PP&E | 0.0 | 0.0 |
| Total assets | 55.5 | 153 |
| Payables | 2.2 | 2.1 |
| Current liabilities | 4.7 | 9.2 |
| Total liabilities | 4.7 | 9.2 |
| Shareholders' equity | −48.5 | −121 |
| Fiscal year | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating cash flow | −23.7 | −71.6 |
| Capital expenditure | 0.0 | 0.0 |
| Free cash flow | −23.7 | −71.6 |
| Stock-based compensation | 0.3 | 1.4 |
| Fiscal year | Dec 2024 | Dec 2025 |
|---|---|---|
| ROCEEBIT ÷ (assets − current liabilities) | −52.7% | −50.4% |
| Cash conversion (CFO ÷ net income) | 0.89x | 1.02x |
| Interest cover | −45.8x | – |
| Current ratio | 11.8x | 16.7x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.